danoprevir + ritonavir + interferon

Danoprevir + ritonavir + interferon is a combination therapy primarily developed for the treatment of chronic hepatitis C virus (HCV) infection, especially genotype 1. Danoprevir is a second-generation HCV NS3/4A protease inhibitor that blocks viral replication by inhibiting the viral protease essential for processing the HCV polyprotein. Ritonavir acts as a pharmacokinetic booster by inhibiting CYP3A4-mediated metabolism of danoprevir, thereby increasing its plasma concentration and efficacy. Interferon (typically peginterferon alfa-2a) is an immunomodulatory cytokine that enhances antiviral immune responses and has direct antiviral effects against HCV. This triple regimen has demonstrated high sustained virologic response rates in both treatment-naive and previously treated patients with chronic hepatitis C[1][2][6].

Brand names

none

Other names

danoprevir/ritonavir/interferonDNVr + peginterferon alfa-2a